Andrea Gaedigk

List of Publications by Year
in descending order

155	9,392	36303	45317
papers	citations	51	90
		h-index	g-index

187	187	187	6536
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet, The, 2006, 368, 704.	13.7	582
2	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	2.4	365
3	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	3.1	353
4	Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 1990, 347, 773-776.	27.8	345
5	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	4.7	335
6	Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics and Genomics, 1998, 8, 15-26.	5.7	281
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	4.7	244
8	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Research, 2010, 20, 1020-1036.	5.5	231
9	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
10	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Antiâ€Inflammatory Drugs. Clinical Pharmacology and Therapeutics, 2020, 108, 191-200.	4.7	195
11	Complexities ofCYP2D6gene analysis and interpretation. International Review of Psychiatry, 2013, 25, 534-553.	2.8	188
12	Unique CYP2D6 activity distribution and genotypeâ€phenotype discordance in black Americans. Clinical Pharmacology and Therapeutics, 2002, 72, 76-89.	4.7	178
13	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
14	PharmVar GeneFocus: CYP2D6. Clinical Pharmacology and Therapeutics, 2020, 107, 154-170.	4.7	156
15	Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (CYP)</scp>2D6 Genotype and Atomoxetine Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 94-102.	4.7	152
16	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. Current Drug Metabolism, 2014, 15, 218-232.	1.2	147
17	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics and Genomics, 1999, 9, 669-682.	1.5	142
18	Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical Pharmacology and Therapeutics, 2004, 76, 536-544.	4.7	134

#	Article	IF	Citations
19	Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N -acetyltransferase-2, and xanthine oxidase with the â€³Cooperstown cocktailâ€• Clinical Pharmacology and Therapeutics, 2000, 68, 375-383.	4.7	125
20	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	4.7	125
21	Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Canadian Family Physician, 2007, 53, 33-5.	0.4	125
22	Variability of CYP3A7 Expression in Human Fetal Liver. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 626-635.	2.5	122
23	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
24	Ten Yearsâ€™ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. Journal of Personalized Medicine, 2018, 8, 15.	2.5	110
25	PharmVar GeneFocus: CYP2B6. Clinical Pharmacology and Therapeutics, 2021, 110, 82-97.	4.7	108
26	The Evolution of PharmVar. Clinical Pharmacology and Therapeutics, 2019, 105, 29-32.	4.7	106
27	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLAâ€B Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
28	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Human Molecular Genetics, 2014, 23, 268-278.	2.9	101
29	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	3.3	96
30	Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. Npj Genomic Medicine, 2016, 1, 15007.	3.8	93
31	CYP2D6*36GENE ARRANGEMENTS WITHIN THECYP2D6LOCUS: ASSOCIATION OFCYP2D6*36WITH POOR METABOLIZER STATUS. Drug Metabolism and Disposition, 2006, 34, 563-569.	3.3	89
32	Ageâ€•and Genotypeâ€Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphateâ€Glucuronosyltransferases in Human Liver. Clinical Pharmacology and Therapeutics, 2019, 105, 131-141.	4.7	87
33	Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Human Mutation, 2016, 37, 315-323.	2.5	86
34	Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genetics in Medicine, 2019, 21, 361-372.	2.4	86
35	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics and Genomics, 1998, 8, 325-333.	5.7	85
36	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics and Genomics, 1998, 8, 305-313.	5.7	82

#	Article	IF	Citations
37	Variability in drug metabolizing enzyme activity in HIV-infected patients. European Journal of Clinical Pharmacology, 2010, 66, 475-485.	1.9	80
38	In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4Î± Expression. Drug Metabolism and Disposition, 2012, 40, 726-733.	3.3	79
39	Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Drug Metabolism and Disposition, 2017, 45, 216-223.	3.3	74
40	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	2.8	73
41	PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	4.7	72
42	CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the â^'1584G Promoter Polymorphism. Clinical Chemistry, 2003, 49, 1008-1011.	3.2	70
43	The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiology of Aging, 2012, 33, 2160-2171.	3.1	68
44	Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics and Genomics, 1998, 8, 403-410.	5.7	66
45	CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics, 2012, 13, 91-111.	1.3	66
46	CYP2D7â€"2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics, 2010, 11, 43-53.	1.3	63
47	Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clinical Pharmacology and Therapeutics, 2021, 110, 542-545.	4.7	62
48	Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Frontiers in Pharmacology, 2010, 1, 121.	3.5	58
49	Precision medicine: does ethnicity information complement genotype-based prescribing decisions?. Therapeutic Advances in Drug Safety, 2018, 9, 45-62.	2.4	58
50	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Canadian Journal of Physiology and Pharmacology, 2001, 79, 841-847.	1.4	57
51	Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N -Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2006, 50, 1130-1135.	3.2	57
52	Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine. Drug Metabolism and Disposition, 2002, 30, 595-601.	3.3	56
53	The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. European Journal of Clinical Pharmacology, 2008, 64, 465-475.	1.9	56
54	Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. Journal of Molecular Diagnostics, 2019, 21, 1034-1052.	2.8	55

#	Article	IF	Citations
55	Pharmacogenetics in American Indian populations. Pharmacogenetics and Genomics, 2013, 23, 403-414.	1.5	54
56	Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. Annals of Human Genetics, 2010, 74, 340-350.	0.8	53
57	PharmVar and the Landscape of Pharmacogenetic Resources. Clinical Pharmacology and Therapeutics, 2020, 107, 43-46.	4.7	50
58	Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsurans. Journal of Clinical Microbiology, 2003, 41, 5478-5487.	3.9	48
59	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genetics in Medicine, 2008, 10, 720-729.	2.4	48
60	Variability of CYP2J2 Expression in Human Fetal Tissues. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 523-532.	2.5	47
61	Pharmacogene Variation Consortium Gene Introduction: <scp>NUDT15</scp>. Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	4.7	45
62	Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessiveâ€“Compulsive Disorder. Neuropsychopharmacology, 2006, 31, 1274-1285.	5.4	43
63	Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 265-274.	2.5	43
64	Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Medical Genetics, 2013, 14, 20.	2.1	42
65	Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics, 2013, 14, 261-276.	1.3	42
66	Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metabolism and Disposition, 2018, 46, 888-896.	3.3	42
67	Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism. Drug Metabolism and Disposition, 2019, 47, 818-831.	3.3	42
68	Interrogation of <scp>CYP</scp>2D6 Structural Variant Alleles Improves the Correlation Between <scp>CYP</scp>2D6 Genotype and <scp>CYP</scp>2D6â€Mediated Metabolic Activity. Clinical and Translational Science, 2020, 13, 147-156.	3.1	42
69	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics and Genomics, 1999, 9, 669???682.	5.7	41
70	Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics, 2014, 15, 1947-1962.	1.3	39
71	CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification. Journal of Molecular Diagnostics, 2015, 17, 740-748.	2.8	38
72	CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics, 2016, 17, 259-275.	1.3	38

#	Article	IF	Citations
73	Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metabolism and Disposition, 2016, 44, 948-958.	3.3	37
74	Identification of CYP2D6 impaired functional alleles in Mexican Americans. European Journal of Clinical Pharmacology, 2005, 61, 797-802.	1.9	35
75	PharmVar GeneFocus: CYP2C9. Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	4.7	34
76	Structural characterization of human aryl sulphotransferases. Biochemical Journal, 1999, 337, 337-343.	3.7	33
77	Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. Journal of Clinical Pharmacology, 2018, 58, 823-833.	2.0	33
78	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Frontiers in Pharmacology, 2016, 7, 111.	3.5	32
79	Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Computational Biology, 2020, 16, e1008399.	3.2	32
80	CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein?. Biochemical and Biophysical Research Communications, 2005, 336, 1241-1250.	2.1	31
81	Evaluation of a [¹³C]â€Ðextromethorphan Breath Test to Assess CYP2D6 Phenotype. Journal of Clinical Pharmacology, 2008, 48, 1041-1051.	2.0	31
82	Population Pharmacokinetics of Oral Baclofen in Pediatric Patients withÂCerebral Palsy. Journal of Pediatrics, 2014, 164, 1181-1188.e8.	1.8	29
83	Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations. European Journal of Clinical Pharmacology, 2010, 66, 859-864.	1.9	28
84	Effects of Oral Vitamin K on S- and R-Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe. Journal of Clinical Pharmacology, 2001, 41, 715-722.	2.0	26
85	Limited Association of the 2988g>a Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects. Clinical Pharmacology and Therapeutics, 2005, 77, 228-230.	4.7	26
86	Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. Clinical Pharmacology and Therapeutics, 2003, 73, 575-576.	4.7	25
87	Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. Drug Metabolism and Disposition, 2017, 45, 1044-1048.	3.3	25
88	SNP genotyping using TaqManÂ® technology: the CYP2D6*17 assay conundrum. Scientific Reports, 2015, 5, 9257.	3.3	24
89	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM and R, 2018, 10, 235-243.	1.6	24
90	Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metabolism and Disposition, 2016, 44, 1070-1079.	3.3	23

#	Article	IF	Citations
91	CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis. Journal of Molecular Diagnostics, 2022, 24, 337-350.	2.8	23
92	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	4.7	22
93	Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy. Frontiers in Pharmacology, 2017, 8, 402.	3.5	21
94	Variants in the CYP2B6 3â€²UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. Clinical Pharmacology and Therapeutics, 2018, 104, 130-138.	4.7	21
95	CYP2D6 update. Pharmacogenetics and Genomics, 2012, 22, 692-694.	1.5	19
96	Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical Pharmacology and Therapeutics, 2019, 105, 1501-1512.	4.7	19
97	Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (United States), 2016, 95, e2473.	1.0	18
98	Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics, 2017, 18, 433-443.	1.3	18
99	Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Frontiers in Pharmacology, 2017, 8, 347.	3.5	18
100	<scp>PharmVar GeneFocus</scp>: <scp>SLCO1B1</scp>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	4.7	18
101	Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clinical Pharmacology and Therapeutics, 1999, 66, 535-541.	4.7	17
102	Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clinical Pharmacology and Therapeutics, 2004, 75, 163-171.	4.7	17
103	Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. European Journal of Clinical Pharmacology, 2009, 65, 97-100.	1.9	17
104	Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls. Pharmacogenomics, 2011, 12, 1617-1622.	1.3	17
105	Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clinical Pharmacokinetics, 2018, 57, 1325-1336.	3.5	16
106	CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics, 2018, 19, 947-960.	1.3	16
107	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 759-768.	2.4	16
108	Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 TestÂ® no-call in the clinical setting. Clinical Chemistry and Laboratory Medicine, 2014, 52, 799-807.	2.3	15

#	Article	IF	Citations
109	Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. Human Mutation, 2019, 40, e37-e51.	2.5	15
110	Retrospective Review of Pharmacogenetic Testing at an Academic Childrenâ€™s Hospital. Clinical and Translational Science, 2021, 14, 412-421.	3.1	15
111	PharmVar GeneFocus: CYP3A5. Clinical Pharmacology and Therapeutics, 2022, 112, 1159-1171.	4.7	14
112	CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6*15 and *35 Genotyping. Frontiers in Pharmacology, 2015, 6, 312.	3.5	13
113	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	4.7	12
114	Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical and Translational Science, 2020, 13, 628-637.	3.1	12
115	Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Scientific Reports, 2021, 11, 4158.	3.3	12
116	Resolution of a clinical AmpliChip CYP450 Testâ„¢ no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics, 2014, 15, 1175-1184.	1.3	11
117	High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics, 2013, 14, 913-922.	1.3	10
118	Long-Distance Phasing of a Tentative â€œEnhancerâ€•Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions. Frontiers in Pharmacology, 2020, 11, 486.	3.5	10
119	Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. Journal of Molecular Diagnostics, 2021, 23, 577-588.	2.8	10
120	Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes. Pharmacogenomics, 2021, 22, 529-541.	1.3	10
121	CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics, 2014, 15, 407-410.	1.3	9
122	PASSPORT-seq: A Novel High-Throughput Bioassay to Functionally Test Polymorphisms in Micro-RNA Target Sites. Frontiers in Genetics, 2018, 9, 219.	2.3	9
123	Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics, 2019, 20, 9-20.	1.3	9
124	Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX. Journal of Molecular Diagnostics, 2021, 23, 952-958.	2.8	9
125	CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics, 2014, 15, 1055-1058.	1.3	7
126	Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 1-12.	0.7	7

#	Article	IF	Citations
127	CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice. Pharmacogenomics Journal, 2021, 21, 484-490.	2.0	7
128	CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar. Frontiers in Pharmacology, 2021, 12, 654054.	3.5	7
129	Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7â€“18 Years. Clinical Pharmacology and Therapeutics, 2020, 107, 1149-1158.	4.7	6
130	Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. Pharmacogenomics, 2021, 22, 323-334.	1.3	6
131	Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metabolism and Disposition, 2022, 50, 24-32.	3.3	6
132	Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 224-232.	0.5	5
133	In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Pharmacogenomics, 2017, 18, 427-431.	1.3	5
134	CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics, 2019, 20, 3-8.	1.3	5
135	The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metabolism and Disposition, 2020, 48, 1113-1120.	3.3	5
136	UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technology. Clinical Chemistry and Laboratory Medicine, 2010, 48, 627-33.	2.3	4
137	Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics, 2016, 17, 1291-1293.	1.3	4
138	Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics, 2018, 19, 197-212.	1.3	4
139	Pharmacogenetics: Chasing Perfection. Clinical Pharmacology and Therapeutics, 2019, 106, 265-270.	4.7	4
140	Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder. Frontiers in Pharmacology, 2021, 12, 743494.	3.5	4
141	The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping. Frontiers in Pharmacology, 2022, 13, 867331.	3.5	4
142	CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 543-551.	0.7	3
143	COMMENTS ON HOSKINS ET AL. [(2005) DRUG METAB DISPOS 33:1564â€“1565]: Fig. 1.. Drug Metabolism and Disposition, 2006, 34, 504-505.	3.3	3
144	The impact of the CYP2D6 â€œenhancerâ€•single nucleotide polymorphism on CYP2D6 activity. Clinical Pharmacology and Therapeutics, 2021, , .	4.7	3

#	Article	IF	Citations
145	CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study. Pharmacogenomics, 2022, 23, 315-325.	1.3	3
146	Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 915-926.	0.7	2
147	Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. Frontiers in Psychiatry, 2021, 12, 830608.	2.6	2
148	A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy. Archives of Women's Mental Health, 2022, 25, 355-365.	2.6	1
149	CYP2D6*9 and *41: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype?. Clinical Pharmacology and Therapeutics, 2022, 111, 1208-1211.	4.7	1
150	Utility of the 13 Câ€pantoprazole breath test as a CYP2C19 phenotyping probe for children. Clinical and Translational Science, 2022, , .	3.1	1
151	Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clinical and Translational Science, 2022, 15, 1787-1795.	3.1	1
152	Pediatric therapeutic drug monitoring, toxicology and pharmacogenomics. , 2021, , 849-908.		0
153	CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity. FASEB Journal, 2013, 27, 663.6.	0.5	0
154	Impact of development and genetic variation on human hepatic CYP2B6 expression and activity.. FASEB Journal, 2013, 27, 270.1.	0.5	0
155	Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy. Pharmaceutics, 2022, 14, 160.	4.5	0